News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Semafore Pharmaceuticals, Inc. to Present SF1126 Clinical Data at American Society of Clinical Oncology Annual Meeting



5/26/2011 9:19:18 AM

INDIANAPOLIS, May 26, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced that Phase 1 clinical data for SF1126 will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 3-7, 2011 in Chicago, Illinois. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The data presentation at ASCO 2011 will highlight the safety, tolerability and activity profile of SF1126 in patients with advanced solid tumors and B-cell malignancies.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES